Many therapeutic proteins are characterized by a short half-life and severe site reactions
in vivo. Reasons are their quick renal excretion, low protease stability and high immunogenicity, respectively. PEGylation, the covalent modification of a protein with polyethylene glycol (PEG), is a well established and proven method to overcome these limitations. In contrast to traditional drug formulation a PEGylation modifies all: the structure, the physico-chemical and the pharmacological properties of a protein. Thus, PEGylation must be considered at an early stage in the development process of biopharmaceuticals.
In collaboration with our partner celares GmbH, Scil Proteins offers customized PEGylation solutions ranging from the consulting on a suitable PEGylation strategy to the development of individual PEGylation processes.
celares provides:
- Screening for optimal PEGylation strategies and conditions
- Process Development for PEGylation and purification of the PEGylated protein
- Preparation of PEGylated protein for in vitro and in vivo experiments up to 250 mg
- Analytical methods required for the characterization of PEGylated proteins
- Chemical synthesis of tailor-made PEG reagents
Many years of experience and laboratory facilities equipped to the latest technical standard will efficiently support your work in PEGylation and in this way accelerate the developmental process of your therapeutic protein.
Proteins produced by Scil Proteins Services are ideal substrates for PEGylation by celares.
Please visit
www.celares.com
